Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).

@article{Gianni2003LongtermRI,
  title={Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).},
  author={Alessandro Massimo Gianni and Michele Magni and Maurizio Martelli and Massimo Di Nicola and Carmelo Carlo-Stella and Silvana Pilotti and Alessandro Rambaldi and Sergio Cortelazzo and Caterina Patti and Guido Parvis and Fabio Benedetti and Saveria Capria and P. Poggi – Corradini and Corrado Tarella and Tiziano Barbui},
  journal={Blood},
  year={2003},
  volume={102 2},
  pages={749-55}
}
Mantle cell lymphoma (MCL) is rarely cured with standard-dose chemotherapy. From January 1997 to February 2000, 28 previously untreated advanced-stage MCL patients younger than 61 years of age were treated at 9 Italian hematologic departments with 3 cycles of standard-dose debulking chemotherapy followed by a high-dose rituximab-supplemented sequence (R-HDS) including intravenous administration of high-dose cyclophosphamide, high-dose cytarabine, high-dose melphalan, and high-dose mitoxantrone… CONTINUE READING